Irinotecanhydrochloridetrihydraat Hikma

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecanhydrochloridetrihydraat Hikma, is a topoisomerase I inhibitor presented as a sterile powder for intravenous infusion. It is used to treat metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecanhydrochloridetrihydraat Hikma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance, regulatory adherence and reliable logistics.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer and related metastatic disease.

- Metastatic colorectal cancer: improves overall survival and disease control when incorporated into combination chemotherapy regimens.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities. - Anemia: decreased red blood cell levels causing weakness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe dehydration from uncontrolled diarrhea. - Acute cholinergic syndrome: abdominal cramps, sweating, and bradycardia. - Hepatic toxicity: elevated liver enzymes or jaundice. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Tumor lysis syndrome: rapid tumor cell breakdown leading to metabolic disturbances.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

- Monitor blood counts: perform regular complete blood counts to detect neutropenia. - Assess liver function: evaluate hepatic enzymes and bilirubin before and during treatment. - Evaluate bowel status: screen for pre‑existing diarrhea or intestinal obstruction. - Dose adjustment: consider reduced dosing in patients with hepatic impairment. - Avoid in hypersensitivity: discontinue if severe allergic reaction occurs. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): can raise active metabolite levels and toxicity. - Concurrent myelosuppressive agents: heighten risk of severe neutropenia. - High‑dose radiation therapy: may exacerbate bone‑marrow suppression. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce irinotecan effectiveness. - Antacids containing aluminum or magnesium: can affect drug absorption. - Warfarin: monitor INR as irinotecan may alter anticoagulation. - Diuretics: watch for electrolyte imbalances during diarrhea. - Herbal supplements (e.g., St. John’s wort): potential enzyme induction affecting drug levels.